You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
邁克生物(300463.SZ):2021年度淨利預增15%-25%
格隆匯 01-28 17:33

格隆匯1月28日丨邁克生物(300463.SZ)披露2021年度業績預吿,預計2021年度實現歸屬於上市公司股東的淨利潤9.13億元-9.92元,同比增長15%-25%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤8.94-9.71元,同比增長15%-25%。

2021年在新冠疫情和政策的雙重影響下,體外診斷產業上下游均面臨較大壓力和不確定性,但挑戰總是與機會並存。這一年公司更加堅定地走自主產品發展這一戰略路徑,經營管理層積極推動“全產品線、全產業鏈”佈局向產品“系列化、系統化、自動化、自主化”發展的進程,持續加大研發投入,補充和完善自主產品種類,不斷提升在產品、技術、成本、服務等方面的競爭力,多平台自主產品均已實現全面的實驗室自動化解決方案。

報吿期內,公司加速自主與代理產品結構優化,重點加大自主常規產品在國內與海外市場的推廣,同時重視分銷體系建設,積極調整市場策略以促進公司全平台產品的渠道競爭力。報吿期內,公司自主產品收入保持穩健增長,增速和營收佔比均超過代理產品,其中分子、免疫、臨檢平台產品收入增速均超過30%;隨着研發投入增加和去代理化,公司經營效率不斷得以改善,在多重因素的綜合影響下,公司2021年業績較上年同期增長15%-25%。

報吿期內,預計非經常性損益對淨利潤的影響為1330萬元左右,主要系政府補助。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account